Q2 Earnings Estimate for Pharvaris Issued By Leerink Partnrs

Pharvaris (NASDAQ:PHVS - Free Report) - Investment analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for shares of Pharvaris in a report issued on Wednesday, June 4th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($0.89) for the quarter, down from their previous estimate of ($0.87). The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris' Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($3.66) EPS and FY2026 earnings at ($3.33) EPS.

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald reduced their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Guggenheim started coverage on Pharvaris in a research note on Wednesday. They issued a "buy" rating and a $32.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and set a $27.00 target price on shares of Pharvaris in a research report on Thursday, June 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $36.20.

Pharvaris Stock Performance

Shares of Pharvaris stock traded up $0.18 during mid-day trading on Monday, hitting $17.23. 6,095 shares of the stock were exchanged, compared to its average volume of 74,961. Pharvaris has a 12 month low of $11.51 and a 12 month high of $25.50. The company has a 50-day simple moving average of $15.75 and a 200 day simple moving average of $17.00. The company has a market capitalization of $900.96 million, a P/E ratio of -6.15 and a beta of -2.86.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after purchasing an additional 189,714 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after acquiring an additional 216,483 shares during the last quarter. Octagon Capital Advisors LP grew its stake in shares of Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after buying an additional 157,530 shares during the last quarter. Rock Springs Capital Management LP lifted its position in Pharvaris by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock valued at $14,859,000 after purchasing an additional 18,200 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock valued at $8,510,000 after buying an additional 118,408 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.